FAQ

Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547

Known as: 1C1-mcMMAF 
An auristatin analogue immunoconjugate directed against Eph receptor A2 (EphA2)-positive cancer cells with potential antineoplastic activity. Anti… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
0120062017

Related topics

Related topics

1 relation

Narrower (1)

MEDI-547

Related mentions per year

Related mentions per year

2006-2017
20002005201020152020
Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547
MEDI-547

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models.
The targeting of therapeutics specifically to diseased tissue is crucial for the development of successful cancer treatments. The… (More)
Is this relevant?
2009
2009
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
BACKGROUND EphA2 is overexpressed in many types of human cancer but is absent or expressed at low levels in normal epithelial… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.
The EphA2 receptor tyrosine kinase is selectively expressed on the surface of many different human tumors. We have previously… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.
The chimeric anti-CD30 monoclonal antibody cAC10, linked to the antimitotic agents monomethyl auristatin E (MMAE) or F (MMAF… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?